Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'. [electronic resource]
Producer: 20190527Description: 1276-1277 p. digitalISSN:- 1532-1827
No physical items for this record
Publication Type: Letter; Comment
There are no comments on this title.
Log in to your account to post a comment.